Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHB-02-CD19 in CD19-expressing B-cell Malignancies
NCT07503353Phase 2Not yet recruiting
- Sponsor
- Sheba Medical Center
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHB-02-CD19 in B-cell malignancy, acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), sponsored by Sheba Medical Center. Primary endpoints: Treatment Related Toxicities at 3 months, Efficacy Evaluation at 1 year and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
SHB-02-CD19
03
Conditions
B-cell malignancyacute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07503353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503353.